Gujarat Terce Laboratories Limited · BSE:GUJTERC
Gujarat Terce Laboratories — Q4 FY2022 Earnings Presentation
11 slides from Gujarat Terce Laboratories's earnings presentation, June 2022
Slide 1: Gujarat Terce Laboratories Limited
GUJARAT TERCE 44 LABORATORIES LIMITED
Slide 2: Disclaimer
Disclaimer This presentation is for informational purposes only and does not constitute an offer or a solicitation to sell or an edition or a solicitation to submit an offer to purchase or subscribe for shares or securities of Gujarat Terce Laboratories Limited or a portion thereof, constitute the b
Slide 3: Company Overview
Company Overview Gujarat Terce has over 3 decades of experience in the Manufacturing and Marketing of branded Generics. Roots of Gujarat Terce Laboratories Limited are entrenched in the founding principles of COMPASSION and EXCELLENCE. Terce has an extensive basket of 50 Brands (125 products) with a
Slide 4: Business Highlights
Business Highlights Figures= % of total sales Figures= % of total sales 80 77 75 78 73 63 Q4FY21 37 60 Acute Segment 61 Other Brands Q4FY22 39 Chronic Segment Precious Brands 40 27 25 23 22 68 20 FY21 32 63 FY22 37 0 Q4FY21 Q4FY22 FY21 FY22 0 25 50 75 As per AICOD FY22 data: Our focus on growth of p
Slide 5: Highlights- PCPM (Per Capita Per Month)
Business Highlights- PCPM (Per Capita Per Month) 2 1.63 1.48 1.5 In FY 22 we registered an increase of 1.22 33.6 % in productivity across all 1.05 geographies YoY. 1 We also expanded in newer geographies in Q4 FY 22. As we 0.5 grow, we will be adding newer geographies in India towards our vision of
Slide 6: Highlights- Sales of Top Four Brands
Business Highlights- Sales of Top Four Brands Figures in lacs 1,000 300 288 822 240 773 750 200 613 178 500 461 114 100 250 0 0 FY19 FY20 FY21 FY22 FY19 FY20 FY21 FY22 Therapeutic Segment- Anticold Therapeutic Segment- Pain Management Type- Acute Type- Acute
Slide 7: Highlights- Sales of Top Four Brands
Business Highlights- Sales of Top Four Brands Figures in lacs 400 250 208 319 200 300 288 171 256 150 145 200 102 139 100 100 50 0 0 FY19 FY20 FY21 FY22 FY19 FY20 FY21 FY22 Therapeutic Segment- Antibiotic Therapeutic Segment- Vitamins ( Nutraceuticals) Type- Acute Type- Chronic
Slide 8: Distribution Network & Region Wise Sales
Distribution Network & Region Wise Sales North 23.2% 17 6 105 139 28 75 75 West 12 1 54.4% 18 Central 1 22.4% 3 1 Stockists/ Region-wise sales distribution(FY22) Distributors
Slide 9: Financial Highlights- Q4 FY22 and FY22
Financial Highlights- Q4 FY 22 and FY 22 Q4 FY22 58% 14% 17% YoY growth Op Revenue EBIDTA PAT FY22 59% 172% 135% YoY growth Op Revenue EBIDTA PAT As per AICOD data, the YoY growth of IPM (Indian Pharmaceutical Market) is 14.6%. Gujarat Terce has out grown IPM and has grown by 59% in FY22. As per IQV
Slide 10: Q4 FY22 and FY22- Income Statement
Q4 FY 22 and FY 22- INCOME STATEMENT
Slide 11: Thank you.
Thank you. Registered Office: Gujarat Terce Laboratories Limited, 122/2 Ravi estate, Bileshwarpura, Chhatral, T.A.: Kalol, Gandhinagar, Gujarat 382729 Corporate office: D/ 801 - 802 & 1202, The First, Behind Keshavbaug party plot, Near Shivalik High- Street, Vastrapur, Ahmedabad, Gujarat 380015 Inve
Gujarat Terce Laboratories — Q4 FY2022 Earnings Presentation on 6ix